

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Roy A. Swaringen, Jr. et al GROUP: 129

SER. NO. : 756,025

EXAMINER: J. Turnipseed

FILED : July 17, 1985

FOR : NOVEL COMPOUNDS

RECEIVED

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

NOV 02 1987

GROUP 120

Sir:

AMENDMENT

Cancel claims 19 to 41 and insert claims 42 to 56 therefore.

<sup>1</sup>  
42. 2,2'[(E)-4-Octenedioylbis(oxytri-  
methylene)]bis[(trans)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-  
1-(3,4,5-trimethoxybenzyl)isoquinolinium] cation in association  
with a pharmaceutically acceptable anion.

<sup>2</sup>  
43. 2,2'[(E)-4-Octenedioylbis(oxytrimethylene)]bis[(trans)-  
1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxy-  
benzyl)isoquinolinium] dichloride.

<sup>3</sup>  
44. (+-)trans, trans-2,2'-(Z)-4-Octenedioylbis(oxytri-  
methylene))bis-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium cation in association  
with a pharmaceutically acceptable anion.

<sup>4</sup>  
45. (+-)trans, trans-2,2'-(Z)-4-Octenedioylbis(oxytri-  
methylene))bis-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-  
(3,4,5-trimethoxybenzyl)isoquinolinium dichloride.

25